EMA recommends extension of dalbavancin indication in children
Angelini Pharma announces that the European Commission (EC) has approved the extension of the indication of Xydalba® (dalbavancin) for the treatment of acute bacterial skin and soft tissue infections in children.
Angelini Industries appoints Jacopo Andreose new CEO of Angelini Pharma
Jacopo Andreose, who will take on the role from February 6, has over twenty years of experience in top management positions in the pharmaceutical industry.
New Headway Report
Ukraine–Russia conflict and climate change may lead to a new wave of mental health disorders in the coming months.
Giovanni Manarini new Chief Human Resources & Organization Officer
In his position, Manarini will report hierarchically to the CEO, Pierluigi Antonelli and will join the Leadership Team-the executive committee-of Angelini Pharma.
The European House – Ambrosetti and Angelini Pharma present Headway Epilepsy Report
The report highlights the need for closer European collaboration to tackle the burden of epilepsy
Angelini Pharma appoints Rafal Kaminski as new Chief Scientific Officer
Rafal Kaminski has broad international experience in drug discovery and innovation and will lead Angelini Pharma’s research and development (R&D) strategy. He will commence his role in January 2022.
Women and children hit hardest by mental health disorders during the pandemic: Headway 2023 Mental Health Index
The COVID 19 pandemic has exacerbated gender-related challenges with its mental health consequences disproportionately affecting women, both at work and at home.
Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund
The fund has been established to invest in early-stage companies in Canada and U.S. markets, that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases.
ONTOZRY® (cenobamate) receives European Commission approval for the treatment of drug-resistant focal-onset seizures in adults
Angelini Pharma announced today that the EC has granted marketing authorization for ONTOZRY®.
Epilepsy: talking about it at work is still a taboo
Four thousand European citizens were interviewed by SWG on behalf of Angelini Pharma on the occasion of the Purple Day, the international day of awareness about epilepsy. According to the majority of respondents, people with epilepsy are perfectly normal people, but 40% would not talk about the disease at work.